Theravance Biopharma, Inc. Reports First Quarter 2016 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Theravance Biopharma (TBPH) Will Make VIBATIV Poster Presentation at ATS 2016
May 11, 2016 8:06 AM EDTTheravance Biopharma, Inc. (NASDAQ: TBPH) announced that new data on VIBATIV (telavancin), the Company's FDA-approved antibiotic, will be the focus of a poster presentation at the American Thoracic Society (ATS) 2016 International Conference. Researchers will present results from post hoc analyses of the previously completed Phase 3 ATTAIN (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia) studies, registrational trials which supported the regulatory approval of telavancin (marketed as VIBATIV) for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). The ATS 2016 International Conference is being held in San Francisco on May 13-18, 2016.
The... More
Theravance Biopharma (TBPH) Misses Q1 EPS by 14c
May 9, 2016 5:18 PM EDTTheravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.10), $0.14 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $18.4 million versus the consensus estimate of $18.69 million.
For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.
... More